Korea offers one of Asia-Pacific's most structured environments for rare disease therapies: a national designation system, a 10% patient copayment for designated conditions, and a pricing pathway built for small populations. Yet the market rarely rewards a standard launch playbook. Having led rare disease launches in Korea for more than a decade, I have seen that success depends less on the product than on how well a company matches its operating model to the way each disease

In this third and final installment, we explore the potential impact of new treatments in the Korean rare disease market, focusing on Cystic Fibrosis, Wilson's Disease, Huntington's Disease, Charcot-Marie-Tooth Disease, Angelman Syndrome, and Sickle Cell Disease. These conditions, which have historically been underserved, represent areas with significant unmet needs. This article looks at the current situation and future possibilities for these conditions in Korea, highlighti

In this second part, I will share a detailed overview based on insights I provided during external consulting engagements. We will focus on other critical areas of unmet needs within the Korean rare disease landscape, specifically Hereditary Angioedema (HAE), Hereditary Transthyretin Amyloidosis (hATTR), and Gaucher Disease. These conditions, which have historically been underserved, are now the focus of innovative treatment strategies aimed at addressing significant unmet ne